ClinicalTrials.gg
RecruitingNCT04685148MAMAUpdated Sep 23, 2021

Maternal Mental Health Trial

A Phase 1/2 interventional study of Transdermal patch estradiol and Transdermal patch placebo in Major Depressive Disorder and Postpartum Depression, sponsored by Vibe G Frøkjær, MD, PhD. Recruiting at 1 site in Denmark. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-09-23.

Sponsored by Vibe G Frøkjær, MD, PhD · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Depressive Disorder, Major with a site in Denmark — 10 open to participants now, 11 under way, none of them phase 3. Depressive Disorder, Major · Denmark.

Planned enrollment
6th of 36
220 · median 80
Started
2021
with 3 others
Phase 1/2
Only one
of the 44
Primary completion
2026-12
later than 2 of 10 live
Registered
28th of 44
by date
Lead sponsor
2 of 44
Vibe G Frøkjær, MD, PhD

Among the 44 studies in Depressive Disorder, Major with a site in Denmark, this one is the 6th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 28th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 44 studies in Depressive Disorder, Major with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Depressive Disorder, Major with a site in Denmark, or all of them as a file.
02

Study summary

Perinatal depression affects 10-15% of women postpartum and has a recurrence rate of 40%. Women who develop perinatal depression might be particularly susceptible to the rapid and large changes in sex steroid hormones, particularly estradiol, across pregnancy to postpartum. This trial aims 1) to evaluate the preventive effect of transdermal estradiol treatment in the immediate postpartum on depressive episodes in a subgroup of women at high-risk for perinatal depression, and 2) to determine if a set of biomarker gene transcripts can identify this subgroup and thus form the basis for future personalised prevention or treatment.

The MAMA Trial is a double-blind, 1:1 randomised, placebo-controlled trial. The trial involves maternity wards at three university hospitals in the Capital Region of Denmark. Women who are singleton pregnant in the third trimester with a prior history of perinatal depression are eligible to participate. Participants will be randomised to either estradiol patches (200 μg per day) or placebo patches for three weeks starting immediately postpartum.

The primary statistical analysis will be performed based on the intention-to-treat principle. A sample size of 220 will provide the trial with 80% power (alpha 0.05, beta 0.2) to detect a reduction in postpartum depression of 50% and to tolerate a drop-out of around 20%.

Read the detailed description

Major depressive disorder affects twice as many women as men. Women are at increased risk for depression in life phases, where endogenous sex steroid hormone milieu changes; such as in puberty, during late pregnancy to postpartum and across menopausal transition. This includes a subtype of MDD, perinatal depression (PND) that affects 10-15% of mothers postpartum and has a recurrence rate of 40% in subsequent pregnancies. PND is a disabling disorder that affects the entire family, including development and future health of the infant.

The underlying risk and resilience mechanisms in MDD are far from clear, consequently, current treatment strategies are suboptimal. Women who develop PND might be particularly sensitive to the rapid and large changes in sex steroid hormone milieu, seen in the transition from high levels of sex steroid hormones, in particular estradiol, in pregnancy to low levels in the hormone withdrawal phase postpartum. Thus, PND is most likely has a distinct pathophysiology, which may provide a unique opportunity for protecting mental health by targeted short-term prevention in the immediate postpartum period.

Intriguingly, recent human data has provided direct evidence for sex hormone manipulation to provoke subclinical depressive symptoms in about 12% of healthy volunteers. The phenomenon was linked to changes in estradiol, which were induced by the pharmacological manipulation with a Gonadotrophin Releasing Hormone agonist. Estradiol affects critical domains and key brain regions known to be dysfunctional in women with major depressive disorder. Estradiol sensitivity predisposes to PND, which can be demonstrated at the level of gene transcription in clinical cohorts, and is also directly supported by recent research results. Such peripheral markers of estradiol sensitivity may prove useful in identifying individuals at excess risk for PND, also in their first pregnancy, and thus may help direct preventive efforts for the women who can benefit the most.

Transdermal estradiol emerges as a promising preventive treatment option for the postpartum onset of PND supported by epidemiological, preclinical, and clinical research, robust and rapid response to estradiol in some pilot postpartum depression (PPD) trials with few side effects and minimal breastmilk passage to the infant. Further, transdermal estradiol appears to be effective in preventing clinically significant depressive symptoms among perimenopausal women, which is another group of women in hormonal transition phase.

Previously, a double-blind randomized, controlled trial (RCT) showed effect of treatment with transdermal estradiol on manifest PND. A recent pilot RCT with transdermal estradiol as a candidate treatment for postpartum depression failed to achieve its primary outcome, but notably, did reduce depressive symptoms postpartum compared to placebo.

Rather than treating manifest depressive episodes postpartum, the investigators here propose a different approach: to target, and potentially prevent, early risk mechanisms in the first three weeks postpartum, and to direct this preventive strategy towards women in high risk. This immediate and early postpartum timing corresponds to the peak risk period and covers the peak of hormonal decline postpartum.

This trial aims 1) to evaluate the preventive effect of transdermal estradiol treatment in the immediate postpartum on depressive episodes in a subgroup of women at high risk for Perinatal Depression with postpartum onset, and 2) to determine if a set of biomarker gene transcripts can identify this subgroup and thus form the basis for future personalized prevention or treatment.

Methods The Maternal Mental Health (MAMA) Trial is designed as a double-blind, 1:1 randomized, placebo-controlled superiority trial setting involving maternity wards at three university hospitals in the Capital Region of Denmark.

Women who are singleton pregnant in third trimester with a prior history of perinatal depression (onset before six months postpartum) and aged 18 to 45 years are eligible to participate.

The women will be assessed for eligibility by the midwife or obstetrician when attending antenatal care at the outpatient clinic. Eligible participants who verbally consent to receive more information about the trial will subsequently be contacted by telephone. Written informed consent is obtained before inclusion in the MAMA Trial.

The randomisation will be conducted by the capital region pharmacy. Trial participants, clinical care providers, research assistants, investigators, outcome assessors, and data analysists will all be blinded to allocation.

The investigators calculated that a sample of 2*88 complete cases would provide the trial with 80% power (at a two-sided alpha level of 0.05) to detect a reduction in postpartum depression of 50%. Thus, with a study number of 2*110, the design is considered solid and can tolerate 22% dropouts.

The primary statistical analysis will be performed on basis of the intention-to-treat principle. The investigators will compare data on the primary outcome for the two groups for the superiority of estradiol over placebo with Pearson's chi-squared test.

Secondary outcomes with a continuous distribution will be compared between groups with respect to the mean (Student's t-test) if the distribution is unimodal and symmetric, or to the median if the distribution is unimodal but asymmetric, or otherwise to the ranks of the observations (Mann-Whitney test). A test on the difference in proportions will be used for binary secondary outcomes and a Pearson's chi-squared test will be used for categorical data.

As a sensitivity analysis, we will use an instrumental variable approach to estimate causal treatment effect using randomisation as an instrument.

Ethical considerations The short-term administration of estradiol transdermally is not expected to pose unacceptable or intolerable side-effects, disrupt breastfeeding or pass to the infant in any dosages that may pose a risk to the infant. Should un-expected side effects for mother or infant occur or be suspected, the treatment will be disrupted immediately. When removing the patch, serum concentrations of estradiol return to baseline levels within 24 hours. Participants who develop levels of mental distress or depressive symptoms that approach clinical thresholds will be referred to relevant and timely psychiatric care by a trained clinician. All potentially sensitive personal data will be anonymized. The trial will adhere closely to the Helsinki declaration.

Prospect There is a pressing need to develop a preventive strategy to depressive episodes during pregnancy and childbirth, that is targeted, cheap, short-term, and easy to implement. Such work holds promise to positively affect women's mental health, their families, and importantly, if successful, may also improve long-term outcomes of the infant's physical and mental health.

03

Conditions studied

  • Major Depressive Disorder
  • Postpartum Depression

Keywords

  • Postpartum period
  • Mother-infant interaction
  • Personalised prevention
  • Perinatal depression
  • Hormone sensitivity
  • Estradiol
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton pregnant
  • Prior history of perinatal depression
  • Age between 18 and 45 years

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe depression with onset during pregnancy
  • Severe psychiatric disorders (e.g. disorders with psychotic symptoms, schizophrenia, bipolar disorders, inpatient eating disorders and inpatient obsessive-compulsive disorders)
  • Previous suicide attempts without having a depressive episode
  • Prior history or ongoing neurological disorders (e.g. migraine or epilepsy)
  • Severe somatic illness
  • Prior history or ongoing cancer
  • Prior history of venous thromboembolism, myocardial infarction, cerebrovascular thromboembolism or thrombophilia, or other risk factors clinically assessed after thrombophilia screening
  • Deep vein thrombosis or pulmonary embolism in current pregnancy
  • Pregnancy-induced hypertension or preeclampsia
  • Pre-existing atherosclerosis or well-known cardiovascular risk factors (e.g. diabetes, hypertension)
  • Other for oestrogen treatment (e.g. acute liver failure, severe varicose veins)
  • Use of psychotropic pharmacology, except for short-term sleep support treatment
  • Non-fluent in Danish or pronounced vision or hearing loss
  • (BMI) >35 kg/m2
  • Ongoing alcohol or drug abuse
  • Severe postpartum haemorrhage (>1500 ml)
  • Severe illness in the infant or perinatal death
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Intervention

    Estradiol patches (200 μg per day) 0-3 weeks postpartum.

    Drug: Transdermal patch estradiol

  • Placebo comparator
    Placebo

    Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum

    Drug: Transdermal patch placebo

Interventions

  • DrugTransdermal patch estradiol

    Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.

  • DrugTransdermal patch placebo

    Placebo patches will be administered at day 0 (+1) to day 21 postpartum.

06

What researchers measure

Primary outcomes

  1. Number of participants with Major Depression Disorder

    Clinical diagnosis assessed by DSM-V criteria

    Time frame: 0-6 months postpartum

Secondary outcomes

  1. EPDS Depressive symptoms

    Edinburgh Postnatal Depression Scale score. Score range: 0-30.

    Time frame: 8-10 weeks postpartum

  2. HamD6 Depressive symptoms

    Score on the Hamilton 6-item depression scale. Score range 0-22.

    Time frame: 8-10 weeks postpartum

  3. Maternal mental wellbeing

    WHO-5 Well-Being Index. Score range 0-100. Low score means less well-being.

    Time frame: 8-10 weeks postpartum

  4. Maternal anxiety

    State Trait Anxiety inventory (STAI) score. Score range 20-80.

    Time frame: 8-10 weeks postpartum

  5. Parental stress

    Parental Stress Scale. Score range 18-90.

    Time frame: 8-10 weeks postpartum

  6. Parental reflective capacity

    Parental Reflective Functioning Questionnaire. Score range 12-60.

    Time frame: 8-10 weeks postpartum

  7. Parental competences

    Parenting Sense of Competence scale. Score range 16-96.

    Time frame: 8-10 weeks postpartum

  8. Proportion of women who exclusively breastfeed their infants

    Questionnaire developed for the trial. Categorical outcome.

    Time frame: 8-10 weeks postpartum

  9. Predictive value of composite gene transcription and DNA methylation marker for estrogen sensitivity

    116 a priori defined gene transcripts, which where differentially expressed in third trimester of women who later developed perinatal depression with postpartum onset relative to pregnant women who did not and to other depressed (reference Mehta et al, 2014, Psychological Medicine, Mehta et al. 2018 British Journal of Psychiatry).

    Time frame: 8-10 weeks postpartum

  10. Maternal sleep quality

    Pittsburgh Sleep Quality Index. Score range 0-21.

    Time frame: 8-10 weeks postpartum

  11. Maternal attachment to unborn child

    Maternal Antenatal Attachment Scale. Score range 19-95.

    Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy

  12. Cold cognitive function

    A later variable derived from simple reaction time test, Rey's Auditory Verbal Learning Task (Declarative memory, RAVLT), Letter-Number Sequence (Working Memory, LNS), and Intra-Extra Dimensional Set Shifting (Cognitive flexibility, IED, error rate)

    Time frame: 8-10 weeks postpartum

  13. Hot cognitive function

    A latent variable derived from emotional Intensity Morphing Test (EIMT) and Infant Emotion Test (Maternal Distress Sensitivity and Infant Emotion Detection (IET)

    Time frame: 8-10 weeks postpartum

  14. Socio-emotional infant development

    Ages and Stages questionnaire Social-emotional 2 (ASQ:SE-2) total score. Score range 0-160. Higher scores worse outcome.

    Time frame: 8-10 weeks

  15. Infant development (Bayley-III)

    Cognitive, language and motor development score from Bayley-III test

    Time frame: 8-10 weeks postpartum

  16. Cortisol dynamics Cortisol dynamics

    Cortisol awakening response in saliva (area under the curve with respect to increase from 0 to 60 minutes from awakening)

    Time frame: 3-5 weeks postpartum

  17. Cortisol evening Cortisol dynamics

    Cortisol concentration in evening saliva from home sampling

    Time frame: 3-5 weeks postpartum

  18. Hair cortisol level Cortisol dynamics

    Provides an estimate of cortisol exposure up to 6 months prior to delivery

    Time frame: 0-1 days postpartum

  19. Epigenetic markers relevant for infant HPA axis

    FKBP5 methylation index

    Time frame: 0-1 days postpartum

  20. Estradiol level

    Estradiol level in peripheral blood

    Time frame: 3 weeks postpartum

  21. Change in estradiol level

    Estradiol change pre- to postpartum in peripheral blood

    Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum

  22. Progesterone level

    Progesterone level in peripheral blood

    Time frame: 3 weeks postpartum

  23. Change in progesterone level

    Progesterone change pre- to postpartum in peripheral blood

    Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum

  24. Allopregnanolone level

    Allopregnanolone level in peripheral blood

    Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy

  25. Allopregnanolone level

    Allopregnanolone level in peripheral blood

    Time frame: 3 weeks postpartum

  26. Change in allopregnanolone level

    Allopregnanolone change pre- to postpartum in peripheral blood

    Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum

  27. Negative bias in responses to infant vocalisations and video

    Composite measure of negative bias score of ratings of 50 infant vocalisations and negative emotional expression.

    Time frame: 8-10 weeks

  28. Estradiol level

    Estradiol level in peripheral blood

    Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy

07

Study locations

1 of 1 sites recruiting
  • Neurobiology Researc hUnit
    Copenhagen, 2100, Denmark
    Recruiting
    • Vibe G Frokjaer, MD, PhD · Contactvibe@nru.dk · 04535456712
08

References and documents

Publications

  • Hogh S, Hegaard HK, Renault KM, Cvetanovska E, Kjaerbye-Thygesen A, Juul A, Borgsted C, Bjertrup AJ, Miskowiak KW, Vaever MS, Stenbaek DS, Dam VH, Binder E, Ozenne B, Mehta D, Frokjaer VG. Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial. BMJ Open. 2021 Dec 30;11(12):e052922. doi: 10.1136/bmjopen-2021-052922. PubMed 35763351 ↗

Individual participant data

Plan to share: Yes — When the planned analyses from the trial are published, the data will become publicly available. According to the Danish legislation, data will be available only by approval by the Danish Data Protection Agency and with a signed agreement.

Supporting information: Study protocol

Time frame: We expected that data will come available December 2026 and be available for approx. 4 years.

Access criteria: Data will be available on reasonable request with approval by the Danish Data Protection Agency and with a signed agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2020
First posted
Dec 28, 2020
StartActual
Feb 3, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Sep 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04685148
Lead sponsor
Vibe G Frøkjær, MD, PhD
Responsible party
Vibe G Frøkjær, MD, PhD (Sponsor-investigator, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Dec 28, 2020
Start date
Feb 3, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 23, 2021

Study contacts

Vibe Gedsø Frøkjær, MD, PhD
Contact
vibe@nru.dk
+45 35456714
Stinne Høgh, RM, MSc
Contact
stinne.hoegh@regionh.dk
+45 22973556
Vibe Gedsø Frøkjær, MD, PhD
principal investigator · Neurobiology Research Unit, copenhagen University hospital, Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion